NCT02295059 2026-04-03
Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention
City of Hope Medical Center
Phase NA Active not recruiting
Clinical Trials
13 trialsNCT01881048 2026-01-29
Window of Opportunity Study Targeting the Inflammatory Milieu
University of Colorado, Denver
Phase EARLY_PHASE1 Completed
NCT01351805 2025-12-03
VITAL
Brigham and Women's Hospital
Phase NA Completed
NCT06055894 2025-11-13
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT00244816 2025-10-23
Taxoprexin® Treatment for Advanced Eye Melanoma
American Regent, Inc.
Phase 2 Completed
NCT00422877 2025-10-16
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
American Regent, Inc.
Phase 2 Terminated
NCT00249262 2025-09-26
Taxoprexin Treatment for Advanced Skin Melanoma
American Regent, Inc.
Phase 2 Completed
NCT07136519 2025-08-22
Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
Affiliated Hospital of Guangdong Medical University
Phase 2 Not yet recruiting
NCT00243867 2025-08-01
Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
American Regent, Inc.
Phase 3 Completed
NCT07036952 2025-07-24
Effect of Omega-3 Supplementation as Add on Therapy on Metabolic Syndrome in Women With Polycystic Ovary Syndrome.
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Phase NA Enrolling by invitation
NCT00087776 2025-07-23
Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma
American Regent, Inc.
Phase 3 Terminated
NCT03831178 2025-06-26
DHA-WIN
AHS Cancer Control Alberta
Phase 2 Active not recruiting
NCT06015971 2025-05-06
Omega-3 Fatty Acids and Nutritional Support in Gastrointestinal Cancer
Maimónides Biomedical Research Institute of Córdoba
Phase NA Recruiting